Thus, we established and maintained all standard ER+ PDX lines with subcutaneous 0.4-mg E2 pellets placed during tumor implantation, followed by E2 in the drinking water from 4 weeks after implantation to the end of the experiment. The gene discussed is ESR1; the disease is neoplasm.